» Articles » PMID: 20103737

AMPK and SIRT1: a Long-standing Partnership?

Overview
Date 2010 Jan 28
PMID 20103737
Citations 396
Authors
Affiliations
Soon will be listed here.
Abstract

AMP-activated protein kinase (AMPK) and the histone/protein deacetylase SIRT1 are fuel-sensing molecules that have coexisted in cells throughout evolution. When a cell's energy state is diminished, AMPK activation restores energy balance by stimulating catabolic processes that generate ATP and downregulating anabolic processes that consume ATP but are not acutely needed for survival. SIRT1 in turn is best known historically for producing genetic changes that mediate the increase in longevity caused by calorie restriction. Although the two molecules have been studied intensively for many years, only recently has it become apparent that they have similar effects on diverse processes such as cellular fuel metabolism, inflammation, and mitochondrial function. In this review we will examine the evidence that these similarities occur because AMPK and SIRT1 both regulate each other and share many common target molecules. In addition, we will discuss the clinical relevance of these interactions and in particular the possibility that their dysregulation predisposes to disorders such as type 2 diabetes and atherosclerotic cardiovascular disease and is a target for their therapy.

Citing Articles

Vicenin-2 Hinders Pro-Inflammatory Response via Targeting the CaMKKβ-AMPK-SIRT1 Axis in Lipopolysaccharide-Stressed THP-1 Cells.

Maugeri A, Russo C, Patane G, Farina M, Rapisarda A, Masullo M Int J Mol Sci. 2025; 26(5).

PMID: 40076701 PMC: 11900626. DOI: 10.3390/ijms26052077.


Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.


Dietary pattern and hepatic lipid metabolism.

Zou P, Wang L Liver Res. 2025; 7(4):275-284.

PMID: 39958775 PMC: 11791920. DOI: 10.1016/j.livres.2023.11.006.


AMPK as a Therapeutic Target: Advancing Epilepsy Management Through Metabolic Modulation.

Dhureja M, Munshi A, Kumar P Mol Neurobiol. 2025; .

PMID: 39937419 DOI: 10.1007/s12035-025-04745-4.


Time Restricted Eating: A Valuable Alternative to Calorie Restriction for Addressing Obesity?.

Parrotta M, Colangeli L, Scipione V, Vitale C, Sbraccia P, Guglielmi V Curr Obes Rep. 2025; 14(1):17.

PMID: 39899119 PMC: 11790783. DOI: 10.1007/s13679-025-00609-z.


References
1.
Purushotham A, Schug T, Xu Q, Surapureddi S, Guo X, Li X . Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9(4):327-38. PMC: 2668535. DOI: 10.1016/j.cmet.2009.02.006. View

2.
Milne J, Lambert P, Schenk S, Carney D, Smith J, Gagne D . Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450(7170):712-6. PMC: 2753457. DOI: 10.1038/nature06261. View

3.
Sun Q, Li L, Li R, Yang M, Liu H, Nowicki M . Overexpression of visfatin/PBEF/Nampt alters whole-body insulin sensitivity and lipid profile in rats. Ann Med. 2009; 41(4):311-20. DOI: 10.1080/07853890902729760. View

4.
Kadowaki T, Yamauchi T, Kubota N . The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett. 2007; 582(1):74-80. DOI: 10.1016/j.febslet.2007.11.070. View

5.
Pold R, Jensen L, Jessen N, Buhl E, Schmitz O, Flyvbjerg A . Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes. 2005; 54(4):928-34. DOI: 10.2337/diabetes.54.4.928. View